Skip to main content
All lobbying filings

BGR GOVERNMENT AFFAIRS

Lobbying for AMGEN INC. · Pharmaceutical Company

 Filing Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Income
$50,000.00
What the client paid this registrant for the period.
Client based in
California

Official filing document

 Lobbyists on this filing 7
  • ROBERT WOOD
    Previously held: Chief of Staff to HHS Secretary; Intern to Rep. Scott Klug
  • BRENT ALAN DEL MONTE
    Previously held: Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee
  • ROBB WALTON
    Previously held: Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes
  • JOHN STONE
    Previously held: Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C
  • REMY LEIGH BRIM MASON
    Previously held: Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz
  • JOEL D. BAILEY
    Previously held: COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA, Sr. LA Rep. Baron Hill; Intern Rep. Rahall
  • RAGHAV AGGARWAL New on this filing
    Previously held: Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1

Provide advice and strategic counsel with regard to matters that could impact biopharmaceutical manufacturers generally and Amgen specifically, including Medicare Part D, Medicare Part B, Health Care Reform, Medicaid, FDA regulatory issues, and corporate tax reform.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem